As a multidrug-resistant and invasive pathogen, Acinetobacter baumannii is one of the leading causes of nosocomial infections in the healthcare system. It has been recognized as a causative agent of pneumonia, sepsis, meningitis, urinary tract and wound infections. It is associated with high morbidity, mortality and healthcare costs due to treatment failure. Biomedical databases (Scopus, Medline, Web of Science, EBSCO, Google Scholar and PubMed) were searched and retrieved for all relevant manuscripts published in English. Eighty-six (86) documents were revived from previous researches of four different search engine, with a follow-up full-text evaluation of 35 publications for inclusion. Due to the lack of data on MDR A. baumannii in Africa, especially Nigeria, 10 articles were selected for this review. The results of ten selected articles showed that 4084 isolates of A. baumannii causing nosocomial infection were isolated from clinical specimens, of which 287 isolates of A. baumannii were detected. Antibiotics tested against identified A. boumannii belong to different classes which include: AMK: amikacin; CEF: ceftriaxone; GEN: gentamicin; IPM: imipenem; LVX: levofloxacin; MEM: meropenem; AMP: ampicillin; CIP: ciprofloxacin; AMX amoxicillin; SAL sulbactam and COL: colistin. The highest resistance was to GEN and the lowest to MEM. This review highlighted the burden of multidrug-resistant Acinetobacter baumannii to antibiotics in Nigeria. There is a need for continuous surveillance study on antimicrobial resistance in Nigeria, especially in primary healthcare which was abandoned by most researchers.